<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="301eb825-8001-ad83-e063-6294a90a14f7"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ATROPINE SULFATE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for ATROPINE SULFATE OPHTHALMIC SOLUTION.
 <br/>
ATROPINE SULFATE ophthalmic solution, for topical application to the eye.
 <br/>
Initial U.S. Approval: 1960
</title>
   <effectiveTime value="20250312"/>
   <setId root="301ea0f4-a1dc-ad4f-e063-6294a90acc1c"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="828374897"/>
            <name>Redpharm Drug</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="828374897"/>
                        <name>Redpharm Drug</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="67296-2124" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="301ec0a5-7025-f391-e063-6294a90ab2a8"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250312"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="67296-2124" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Atropine Sulfate</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Atropine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="70756-652" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RN3152OP35" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (4000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="22ADO53M6F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="593YOG76RN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="03J5ZE7KA5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ATROPINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7C0697DR9I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ATROPINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="67296-2124-5" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240108"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102842" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA218148" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID87">
               <id root="301ea0c3-6629-ad85-e063-6294a90a47e6"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID88">Atropine Sulfate Ophthalmic Solution 1% is indicated for:</paragraph>
               </text>
               <effectiveTime value="20230808"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID93"> Atropine is an anti-muscarinic agent indicated for:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Cycloplegia (1.1)</item>
                           <item>Mydriasis (1.2)</item>
                           <item>Penalization of the healthy eye in the treatment of amblyopia (1.3)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID89">
                     <id root="301ea0c3-662a-ad85-e063-6294a90a47e6"/>
                     <title>1.1 Cycloplegia</title>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID90">
                     <id root="301ea0c3-662b-ad85-e063-6294a90a47e6"/>
                     <title>1.2 Mydriasis</title>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID91">
                     <id root="301ea0c3-662c-ad85-e063-6294a90a47e6"/>
                     <title>1.3 Penalization of the healthy eye in the treatment of amblyopia</title>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID6">
               <id root="301ea0c3-662d-ad85-e063-6294a90a47e6"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph ID="ID7">2.1 In individuals from three (3) months of age or greater, 1 drop topically to the cul-de-sac of the conjunctiva, forty minutes prior to the intended maximal dilation time.</paragraph>
                  <paragraph>2.2 In individuals 3 years of age or greater, doses may be repeated up to twice daily as needed.</paragraph>
               </text>
               <effectiveTime value="20230808"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>In individuals from three (3) months of age or greater, 1 drop topically to the cul-de-sac of the conjunctiva, forty minutes prior to the intended maximal dilation time (2)</item>
                           <item>In individuals 3 years of age or greater, doses may be repeated up to twice daily as needed. (2)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID10">
               <id root="301ea0c3-662e-ad85-e063-6294a90a47e6"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID11">Atropine Sulfate Ophthalmic Solution, USP 1%: each mL contains 10 mg of atropine sulfate equivalent to 8.3 mg of atropine.</paragraph>
               </text>
               <effectiveTime value="20230125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID13">1% ophthalmic solution (3)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID14">
               <id root="301ea0c3-662f-ad85-e063-6294a90a47e6"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20230125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID18"> Hypersensitivity or allergic reaction to any ingredient in formulation (4.1)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID15">
                     <id root="301ea0c3-6630-ad85-e063-6294a90a47e6"/>
                     <title>4.1 Hypersensitivity to any Component of this Medication</title>
                     <text>
                        <paragraph ID="ID16">Atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur.</paragraph>
                     </text>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID19">
               <id root="301ea0c3-6631-ad85-e063-6294a90a47e6"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Photophobia and blurred vision due to pupil unresponsiveness and cycloplegia may last up to 2 weeks. (5.1)</item>
                           <item>Risk of blood pressure increase from systemic absorption (5.2)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID20">
                     <id root="301ea0c3-6632-ad85-e063-6294a90a47e6"/>
                     <title>5.1 Photophobia and Blurred Vision</title>
                     <text>
                        <paragraph ID="ID21">Photophobia and blurred vision due to pupil unresponsiveness and cycloplegia may last up to 2 weeks.</paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID22">
                     <id root="301ea0c3-6633-ad85-e063-6294a90a47e6"/>
                     <title>5.2 Elevation of Blood Pressure</title>
                     <text>
                        <paragraph ID="ID23">Elevation in blood pressure from systemic absorption has been reported following conjunctival instillation of recommended doses of atropine sulfate ophthalmic solution, 1%.</paragraph>
                     </text>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID26">
               <id root="301ea0c3-6634-ad85-e063-6294a90a47e6"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID27">The following serious adverse reactions are described below and elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Photophobia and Blurred Vision
  
   <content styleCode="italics">[See Warnings and Precautions (5.1)]</content>
                     </item>
                     <item>Elevation in Blood Pressure
  
   <content styleCode="italics">[See Warnings and Precautions (5.2)]</content>
                     </item>
                  </list>
                  <paragraph ID="ID29">The following adverse reactions have been identified following use of atropine sulfate ophthalmic solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
               </text>
               <effectiveTime value="20230125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID84">Most common adverse reactions that have been reported are eye pain and stinging on administration, blurred vision, photophobia, decreased lacrimation, increased heart rate and blood pressure (6)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact</content>
                           <content styleCode="bold">Lifestar Pharma LLC at 1-888-995-4337</content>
                           <content styleCode="bold">or FDA at 1-800-FDA-1088 or
  
     <content styleCode="italics">www.fda.gov/medwatch</content>.
 
    </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID30">
                     <id root="301ea0c3-6635-ad85-e063-6294a90a47e6"/>
                     <title>6.1 Ocular Adverse Reactions</title>
                     <text>
                        <paragraph ID="ID31">Eye pain and stinging occurs upon instillation of atropine sulfate ophthalmic solution. Other commonly occurring adverse reactions include, blurred vision, photophobia, superficial keratitis and decreased lacrimation. Allergic reactions such as papillary conjunctivitis, contact dermatitis, and lid edema may also occur less commonly.</paragraph>
                     </text>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID32">
                     <id root="301ea0c3-6636-ad85-e063-6294a90a47e6"/>
                     <title>6.2 Systemic Adverse Reactions</title>
                     <text>
                        <paragraph ID="ID33">Systemic effects of atropine are related to its anti-muscarinic activity. Systemic adverse events reported include dryness of skin, mouth, and throat from decreased secretions from mucus membranes; restlessness, irritability or delirium from stimulation of the central nervous system; tachycardia; flushed skin of the face and neck.</paragraph>
                     </text>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID34">
               <id root="301ea0c3-6637-ad85-e063-6294a90a47e6"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20230125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID49">The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis. (7)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID35">
                     <id root="301ea0c3-6638-ad85-e063-6294a90a47e6"/>
                     <title>7.1 Monamine oxidase inhibitors</title>
                     <text>
                        <paragraph ID="ID36">The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis.</paragraph>
                     </text>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID37">
               <id root="301ea0c3-6639-ad85-e063-6294a90a47e6"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20230808"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID86">Should only be used in pregnant women if clearly needed (8)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID38">
                     <id root="301ea0c3-663a-ad85-e063-6294a90a47e6"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID39">Pregnancy Category C:</paragraph>
                        <paragraph>There are no adequate and well-controlled studies of atropine sulfate in pregnant women. Animal development and reproduction studies have not been conducted with atropine sulfate. Since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution, 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20230808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID40">
                     <id root="301ea0c3-663b-ad85-e063-6294a90a47e6"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph ID="ID41">Traces of atropine have been found in human milk following administration of atropine solution for injection. Because some systemic absorption occurs from topical administration, caution should be exercised when Atropine Sulfate Ophthalmic Solution 1% is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20230808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID42">
                     <id root="301ea0c3-663c-ad85-e063-6294a90a47e6"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID43">Due to the potential for systemic absorption of atropine sulfate ophthalmic solution, the use of atropine sulfate ophthalmic solution, 1% in children under the age of 3 months is not recommended and the use in children under 3 years of age should be limited to no more than one drop per eye per day.</paragraph>
                     </text>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID44">
                     <id root="301ea0c3-663d-ad85-e063-6294a90a47e6"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID45">No overall differences in safety and effectiveness have been observed between elderly and younger adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID46">
               <id root="301ea0c3-663e-ad85-e063-6294a90a47e6"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID47">In the event of accidental ingestion or toxic overdosage with atropine sulfate ophthalmic solution supportive care may include a short acting barbiturate or diazepam as needed to control marked excitement and convulsions. Large doses for sedation should be avoided because central depressant action may coincide with the depression occurring late in atropine poisoning. Central stimulants are not recommended.</paragraph>
                  <paragraph>Physostigmine, given by slow intravenous injection of 1 to 4 mg (0.5 to 1 mg in pediatric populations), rapidly abolishes delirium and coma caused by large doses of atropine. Since physostigmine is rapidly destroyed, the patient may again lapse into coma after one to two hours, and repeated doses may be required.</paragraph>
                  <paragraph>Artificial respiration with oxygen may be necessary. Cooling measures may be needed to help to reduce fever, especially in pediatric populations.</paragraph>
                  <paragraph>The fatal adult dose of atropine is not known. In pediatric populations, 10 mg or less may be fatal.</paragraph>
               </text>
               <effectiveTime value="20230125"/>
            </section>
         </component>
         <component>
            <section ID="ID50">
               <id root="301ea0c3-663f-ad85-e063-6294a90a47e6"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID51">Atropine Sulfate Ophthalmic Solution, USP 1% is a sterile topical anticholinergic for ophthalmic use. The active ingredient is represented by the chemical structure</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID53">
                     <content styleCode="bold">Chemical Name:</content>Benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo[3.2.1.]oct-3-yl ester,
 
  <content styleCode="italics">endo</content>–(±)-, sulfate (2:1) (salt), monohydrate.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Molecular Formula:</content>(C
 
  <sub>17</sub>H
 
  <sub>23</sub>NO
 
  <sub>3</sub>)
 
  <sub>2</sub>  H
 
  <sub>2</sub>SO
 
  <sub>4</sub> H
 
  <sub>2</sub>O

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Molecular Weight:</content>694.84 g/mol

 </paragraph>
                  <paragraph>Atropine sulfate, USP appears as colorless, almost white to white solid. It is very soluble in water and glacial acetic acid, freely soluble in ethanol (96%) and practically insoluble in diethyl ether.</paragraph>
                  <paragraph>Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains:
 
  <content styleCode="bold">Active</content>: atropine sulfate, USP 10 mg equivalent to 8.3 mg of atropine.
 
  <content styleCode="bold">Inactives:</content>benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate anhydrous, edetate disodium dihydrate, hypromellose (2910), monobasic sodium phosphate monohydrate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection USP.

 </paragraph>
               </text>
               <effectiveTime value="20230808"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="46620afa-ac10-4204-90bf-47f0c9f8c542-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID54">
               <id root="301ea0c3-6640-ad85-e063-6294a90a47e6"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20230808"/>
               <component>
                  <section ID="ID55">
                     <id root="301ea0c3-6641-ad85-e063-6294a90a47e6"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID56">Atropine is a reversible antagonist of muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors.</paragraph>
                        <paragraph>The pupillary constrictor muscle depends on muscarinic cholinoceptor activation. This activation is blocked by topical atropine resulting in unopposed sympathetic dilator activity and mydriasis. Atropine also weakens the contraction of the ciliary muscle, or cycloplegia. Cycloplegia results in loss of the ability to accommodate such that the eye cannot focus for near vision.</paragraph>
                     </text>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID57">
                     <id root="301ea0c3-6642-ad85-e063-6294a90a47e6"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID58">The onset of action after administration of atropine sulfate ophthalmic solution 1%, is usually within 40 minutes with maximal effect being reached in about 2 hours. The effect can last for up to 2 weeks in a normal eye.</paragraph>
                     </text>
                     <effectiveTime value="20230808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID59">
                     <id root="301ea0c3-6643-ad85-e063-6294a90a47e6"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID60">The bioavailability of atropine sulfate ophthalmic solution, 1% was assessed in six healthy subjects, 24 to 29 years of age. Subjects received either 0.3 mg atropine sulfate administered as bolus intravenous injection or 0.3 mg administered as 30 μl instilled unilaterally in the cul-de-sac of the eye. Plasma l-hyoscyamine concentrations were determined over selected intervals up to eight hours after dose administration.</paragraph>
                        <paragraph>The mean bioavailability of topically applied atropine was 63.5 ± 29% (range 19 to 95%) with large inter-individual differences. Mean maximum observed plasma concentration for the ophthalmic solution was 288 ± 73 pg/mL. Maximum concentration was reached in 28 ± 27 min after administration. Terminal half-life of l-hyoscamine was not affected by route of administration and was calculated to be 3 ± 1.2 hours (intravenous) and 2.5 ± 0.8 hours (topical ophthalmic).</paragraph>
                        <paragraph>In another placebo-controlled study, the systemic exposure to l-hyoscyamine, and the anti-cholinergic effects of atropine were investigated in eight ocular surgery patients 56 to 66 years of age, following single topical ocular 0.4 mg atropine dose (given as 40 microliters of atropine sulfate ophthalmic solution, 1%). The mean (± standard deviation (SD)) C
 
  <sub>max</sub>of l-hyoscyamine in these patients was 860 ± 402 pg/mL, achieved within 8 minutes of eyedrop instillation.

 </paragraph>
                        <paragraph>Following intravenous administration, the mean (± SD) elimination half-life (t
 
  <sub>1/2</sub>) of atropine was reported to be longer in pediatric subjects under 2 years (6.9 ± 3.3 hours) and in geriatric patients 65 to 75 years (10.0 ± 7.3 hours), compared to in children over 2 years (2.5 ± 1.2 hours) and in adults 16 to 58 years (3.0 ± 0.9 hours).
 
  <content styleCode="italics">(see 8.4 Pediatric Use).</content>
                        </paragraph>
                        <paragraph>Atropine is destroyed by enzymatic hydrolysis, particularly in the liver; from 13 to 50% is excreted unchanged in the urine. Traces are found in various secretions, including milk. The major metabolites of atropine are noratropine, atropin-n-oxide, tropine, and tropic acid. Atropine readily crosses the placental barrier and enters the fetal circulation, but is not found in amniotic fluid.</paragraph>
                        <paragraph>Atropine binds poorly (about 44%) to plasma protein, mainly to alpha-1 acid glycoprotein; age has no effect on the serum protein binding of atropine. Atropine binding to α-1 acid glycoprotein was concentration dependent (2 to 20 mcg/mL) and nonlinear
 
  <content styleCode="italics">in vitro</content>and
 
  <content styleCode="italics">in vivo</content>. There is no gender effect on the pharmacokinetics of atropine administered by injection.

 </paragraph>
                     </text>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID61">
               <id root="301ea0c3-6644-ad85-e063-6294a90a47e6"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230125"/>
               <component>
                  <section ID="ID62">
                     <id root="301ea0c3-6645-ad85-e063-6294a90a47e6"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID63">Atropine sulfate was negative in the Salmonella/microsome mutagenicity test. Studies to evaluate carcinogenicity and impairment of fertility have not been conducted.</paragraph>
                     </text>
                     <effectiveTime value="20230125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID64">
               <id root="301ea0c3-6646-ad85-e063-6294a90a47e6"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID65">Topical administration of atropine sulfate ophthalmic solution, 1% results in cycloplegia and mydriasis which has been demonstrated in several controlled clinical studies in adults and pediatric patients. Maximal mydriasis usually occurs in about 40 minutes and maximal cycloplegia is usually achieved in about 60 to 90 minutes after single administration. Full recovery usually occurs in approximately one week, but may last a couple of weeks.</paragraph>
               </text>
               <effectiveTime value="20230125"/>
            </section>
         </component>
         <component>
            <section ID="ID66">
               <id root="301ea0c3-6647-ad85-e063-6294a90a47e6"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID67">Atropine Sulfate Ophthalmic Solution, USP 1% is supplied as clear, colorless solution in a three piece white bottle with a natural nozzle and red cap in the following sizes:</paragraph>
                  <paragraph>NDC 70756-651-25    2 mL fill in 5 mL bottle</paragraph>
                  <paragraph>NDC 70756-652-25    5 mL fill in 5 mL bottle</paragraph>
                  <paragraph>NDC 70756-653-35    15 mL fill in 15 mL bottle</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep container tightly closed.

 </paragraph>
               </text>
               <effectiveTime value="20230125"/>
            </section>
         </component>
         <component>
            <section ID="ID68">
               <id root="301ea0c3-6648-ad85-e063-6294a90a47e6"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID69">Advise patients not to touch the dropper tip to any surface as this may contaminate the solution.</paragraph>
                  <paragraph>Advise patients that drops will sting upon instillation and advise patients that they will experience sensitivity to light and blurred vision which may last for a couple of weeks.</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lifestar Pharma LLC</content>
                  </paragraph>
                  <paragraph>1200 MacArthur Blvd.</paragraph>
                  <paragraph>Mahwah, NJ 07430 USA</paragraph>
                  <paragraph>
                     <content styleCode="bold">Made in India</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Revised:</content>08/2023, V-02

 </paragraph>
               </text>
               <effectiveTime value="20230808"/>
            </section>
         </component>
         <component>
            <section ID="ID70">
               <id root="301ea0c3-6649-ad85-e063-6294a90a47e6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID71">
                     <content styleCode="bold">NDC 70756-651-25</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Atropine Sulfate Ophthalmic Solution, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID73">
                     <content styleCode="bold">NDC 70756-651-25</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Atropine Sulfate Ophthalmic Solution, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph ID="ID75">
                     <content styleCode="bold">NDC 70756-652-25</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Atropine Sulfate Ophthalmic Solution, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <paragraph ID="ID77">
                     <content styleCode="bold">NDC 70756-652-25</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Atropine Sulfate Ophthalmic Solution, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <paragraph ID="ID79">
                     <content styleCode="bold">NDC 70756-653-35</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Atropine Sulfate Ophthalmic Solution, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">15 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
                  <paragraph ID="ID81">
                     <content styleCode="bold">NDC 70756-653-35</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Atropine Sulfate Ophthalmic Solution, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">15 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
               </text>
               <effectiveTime value="20230808"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>2mlbottlelabel</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="46620afa-ac10-4204-90bf-47f0c9f8c542-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>2mlcartonlabel</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="46620afa-ac10-4204-90bf-47f0c9f8c542-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>5mlbottlelabel</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="46620afa-ac10-4204-90bf-47f0c9f8c542-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>5mlcartonlabel</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="46620afa-ac10-4204-90bf-47f0c9f8c542-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>15mlbottlelabel</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="46620afa-ac10-4204-90bf-47f0c9f8c542-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>15mlcartonlabel</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="46620afa-ac10-4204-90bf-47f0c9f8c542-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>